Myanmar Pharmaceuticals and Healthcare Report

 Published On: Feb, 2015 |    No of Pages: 65 |  Published By: BMI Pharmaceuticals and Healthcare | Format: PDF   |   Request Free Sample

View: New investment reforms lifting restrictions on the foreign funding of medicine production will
make Myanmar an attractive market to international generic drugmakers. This is due to the opportunity of
securing a first-mover advantage in this frontier market, as well as being a result of rising medicine
consumption. Nonetheless, we highlight that there is significant political uncertainty in Myanmar with the
upcoming 2015 elections which poses as a risk to investment.
Headline Expenditure Projections
Pharmaceutical sales: MMK387.5bn (USD390mn) in 2014 to MMK457.3bn (USD440mn) in 2015;
+18.0% in local currency terms and +10.8% in US dollar terms.
Healthcare Expenditure: MMK1,217.9bn (USD1.2bn) in 2014 to MMK1,388.7bn (USD1.3bn) in 2015;
+14.0% in local currency terms and +7.1% in US dollar terms.

Industry View 7
SWOT 9
Industry Forecast 10
Pharmaceutical Market Forecast 10
Table: Pharmaceutical Sales, Historical Data And Forecasts (Myanmar 2011-2019) 11
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Myanmar 2011-2019) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Myanmar 2011-2019) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Myanmar 2011-2019) 17
Pharmaceutical Trade Forecast 18
Table: Pharmaceutical Trade Data And Forecasts (Myanmar 2013-2019) 19
Table: Pharmaceutical Trade Data And Forecasts local currency (Myanmar 2013-2019) 19
Macroeconomic Forecasts 20
Economic Activity 20
Recent Stability A Confidence Booster 20
Kyat Yet To Become Major Player In Economy 21
Risks To Outlook 22
Industry Risk Reward Ratings 23
Asia Pacific Risk/Reward Index 23
Myanmar Risk/Reward Index 29
Rewards 29
Risks 29
Market Overview 31
Industry Trends And Developments 32
Epidemiology 32
Communicable Diseases And Other Injuries 32
Table: Leading Causes Of Morbidity And Mortality In 2010 33
Non-Communicable Diseases 33
Regulatory Development 35
Regional Harmonisation 37
Intellectual Property Regime 38
Health Regulation 38
Table: List Of Health And Health-Related Legislation 39
Table: Series Of Revisions To Myanmar's EML 40
Healthcare Outlook 40
Recent Healthcare Developments 41
Competitive Landscape 46
Latest Company Developments 46
Company Profile 49
Fame Pharmaceutical 49
Mega Lifesciences 51
Demographic Forecast 54
Table: Population Headline Indicators (Myanmar 1990-2025) 55
Table: Key Population Ratios (Myanmar 1990-2025) 55
Table: Urban/Rural Population & Life Expectancy (Myanmar 1990-2025) 56
Table: Population By Age Group (Myanmar 1990-2025) 56
Table: Population By Age Group % (Myanmar 1990-2025) 57
Glossary 59
Methodology 61
Pharmaceutical Expenditure Forecast Model 61
Healthcare Expenditure Forecast Model 61
Notes On Methodology 62
Risk/Reward Index Methodology 63
Index Overview 64
Table: Pharmaceutical Risk/Reward Index Indicators 64
Indicator Weightings 65

If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.